Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Antibody response and intra-host viral evolution after plasma therapy in COVID-19 patients pre-exposed or not to B-cell depleting agents

David Gachoud, Trestan Pillonel, Tsilimidos Gerasimos, Dunia Battola, Dominique Dumas, Onya Opota, Stefano Fontana, Peter Vollenweider, Oriol Manuel, Gilbert Greub, Claire Bertelli, Nathalie Rufer
doi: https://doi.org/10.1101/2022.04.24.22274200
David Gachoud
1Department of Internal Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
2Medical Education Unit, School of Medicine, Faculty of Biology and Medicine, University of Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Nathalie.Rufer@unil.ch Gilbert.Greub@chuv.ch david.gachoud@chuv.ch
Trestan Pillonel
3Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tsilimidos Gerasimos
4Division of Hematology, Department of Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dunia Battola
1Department of Internal Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dominique Dumas
1Department of Internal Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Onya Opota
3Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefano Fontana
5Interregional Blood Transfusion SRC, Bern, Switzerland
6Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Vollenweider
1Department of Internal Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oriol Manuel
7Infectious Diseases Service and Transplantation Center, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gilbert Greub
3Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
7Infectious Diseases Service and Transplantation Center, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Nathalie.Rufer@unil.ch Gilbert.Greub@chuv.ch david.gachoud@chuv.ch
Claire Bertelli
3Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nathalie Rufer
8Interregional Blood Transfusion SRC, Epalinges, Switzerland
9Department of Oncology, Lausanne University Hospital and University of Lausanne, Epalinges, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Nathalie.Rufer@unil.ch Gilbert.Greub@chuv.ch david.gachoud@chuv.ch
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Administration of plasma therapy may contribute to viral control and survival of COVID-19 patients receiving B-cell depleting agents that hinder the endogenous humoral response. However, little is known on the impact of anti-CD20 pre-exposition and the use of different sources of plasma (convalescent versus vaccinated) on the kinetics of SARS-CoV-2-specific antibodies and viral evolution after plasma therapy.

Methods Eligible COVID-19 patients (n = 36), half of them after anti-CD20 targeted therapy, were treated with therapeutic plasma from convalescent (n = 17) or mRNA-vaccinated (n = 19) donors. Each plasma-transfused patient was thoroughly monitored over time by anti-S IgG quantification and whole-genome SARS-CoV-2 sequencing.

Results The majority of anti-CD20 pre-exposed patients (15/18) showed progressive declines of anti-S protein IgG titers following plasma therapy, indicating that they mostly relied on the passive transfer of anti-SARS-CoV-2 antibodies. Such antibody kinetics correlated with prolonged infection before virus clearance, contrasting with the endogenous humoral response predominantly present in patients who had not received B-cell depleting agents (15/18). No relevant differences were observed between patients treated with plasma from convalescent and/or vaccinated donors. Finally, 4/30 genotyped patients showed increased intra-host viral evolution and 3/30 included 1 to 4 spike mutations, potentially associated to immune escape.

Conclusions Convalescent and/or vaccinated plasma therapy may provide anti-SARS-CoV-2 antibodies and clinical benefit to B-cell depleted COVID-19 patients. Only a limited number of patients acquired viral mutations prior to clinical recovery, yet our study further emphasizes the need for long-term surveillance for intra-host variant evolution, to guide best therapeutic strategies.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was supported by the Lausanne University Hospital and University of Lausanne (Lausanne, Switzerland), and Interregional Blood Transfusion SRC (Bern, Switzerland).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Cantonal ethics committee for clinical research of the canton Vaud (CER-VD, Lausanne, Switzerland) gave ethical approval for this work. Each patient or legally authorised representative provided informed consent prior to plasma transfusion and for the retrospective data collection. All patients described in this case series were treated with plasma therapy between November, 2020 and July, 2021 under an experimental therapy protocol available as compassionate use only, according to the Swiss Federal Law on Therapeutic Products (LPTh).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted April 26, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Antibody response and intra-host viral evolution after plasma therapy in COVID-19 patients pre-exposed or not to B-cell depleting agents
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Antibody response and intra-host viral evolution after plasma therapy in COVID-19 patients pre-exposed or not to B-cell depleting agents
David Gachoud, Trestan Pillonel, Tsilimidos Gerasimos, Dunia Battola, Dominique Dumas, Onya Opota, Stefano Fontana, Peter Vollenweider, Oriol Manuel, Gilbert Greub, Claire Bertelli, Nathalie Rufer
medRxiv 2022.04.24.22274200; doi: https://doi.org/10.1101/2022.04.24.22274200
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Antibody response and intra-host viral evolution after plasma therapy in COVID-19 patients pre-exposed or not to B-cell depleting agents
David Gachoud, Trestan Pillonel, Tsilimidos Gerasimos, Dunia Battola, Dominique Dumas, Onya Opota, Stefano Fontana, Peter Vollenweider, Oriol Manuel, Gilbert Greub, Claire Bertelli, Nathalie Rufer
medRxiv 2022.04.24.22274200; doi: https://doi.org/10.1101/2022.04.24.22274200

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (434)
  • Anesthesia (99)
  • Cardiovascular Medicine (948)
  • Dentistry and Oral Medicine (178)
  • Dermatology (109)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (420)
  • Epidemiology (8983)
  • Forensic Medicine (4)
  • Gastroenterology (420)
  • Genetic and Genomic Medicine (1953)
  • Geriatric Medicine (190)
  • Health Economics (401)
  • Health Informatics (1328)
  • Health Policy (659)
  • Health Systems and Quality Improvement (519)
  • Hematology (212)
  • HIV/AIDS (420)
  • Infectious Diseases (except HIV/AIDS) (10801)
  • Intensive Care and Critical Care Medicine (575)
  • Medical Education (200)
  • Medical Ethics (54)
  • Nephrology (222)
  • Neurology (1827)
  • Nursing (110)
  • Nutrition (272)
  • Obstetrics and Gynecology (353)
  • Occupational and Environmental Health (470)
  • Oncology (997)
  • Ophthalmology (297)
  • Orthopedics (111)
  • Otolaryngology (182)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (579)
  • Pharmacology and Therapeutics (275)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1898)
  • Public and Global Health (4122)
  • Radiology and Imaging (675)
  • Rehabilitation Medicine and Physical Therapy (368)
  • Respiratory Medicine (548)
  • Rheumatology (225)
  • Sexual and Reproductive Health (190)
  • Sports Medicine (177)
  • Surgery (207)
  • Toxicology (39)
  • Transplantation (109)
  • Urology (80)